ALK-Abelló A/S (AKBLF)
USD 22.05
(0.0%)
USD 22.05
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 486 Million DKK | 45.07% |
| 2022 | 335 Million DKK | 52.97% |
| 2021 | 219 Million DKK | 776.0% |
| 2020 | 25 Million DKK | 150.0% |
| 2019 | -50 Million DKK | 70.59% |
| 2018 | -170 Million DKK | -7.59% |
| 2017 | -158 Million DKK | -158.52% |
| 2016 | 270 Million DKK | -21.51% |
| 2015 | 344 Million DKK | 90.06% |
| 2014 | 181 Million DKK | 196.72% |
| 2013 | 61 Million DKK | -70.81% |
| 2012 | 209 Million DKK | 4.5% |
| 2011 | 200 Million DKK | 56.25% |
| 2010 | 128 Million DKK | 8.47% |
| 2009 | 118 Million DKK | 24.21% |
| 2008 | 95 Million DKK | -46.33% |
| 2007 | 177 Million DKK | 637.5% |
| 2006 | 24 Million DKK | -99.44% |
| 2005 | 4.3 Billion DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 201 Million DKK | -13.36% |
| 2024 Q1 | 232 Million DKK | 65.71% |
| 2023 Q3 | 117 Million DKK | 77.27% |
| 2023 Q2 | 66 Million DKK | -59.51% |
| 2023 Q1 | 163 Million DKK | 108.97% |
| 2023 FY | 486 Million DKK | 45.07% |
| 2023 Q4 | 140 Million DKK | 19.66% |
| 2022 FY | 335 Million DKK | 52.97% |
| 2022 Q3 | 52 Million DKK | 23.81% |
| 2022 Q1 | 163 Million DKK | 114.47% |
| 2022 Q2 | 42 Million DKK | -74.23% |
| 2022 Q4 | 78 Million DKK | 50.0% |
| 2021 Q3 | 37 Million DKK | 276.19% |
| 2021 FY | 219 Million DKK | 776.0% |
| 2021 Q4 | 76 Million DKK | 105.41% |
| 2021 Q2 | -21 Million DKK | -116.54% |
| 2021 Q1 | 127 Million DKK | 509.68% |
| 2020 Q3 | -20 Million DKK | -100.0% |
| 2020 FY | 25 Million DKK | 150.0% |
| 2020 Q1 | 86 Million DKK | 396.55% |
| 2020 Q2 | -10 Million DKK | -111.63% |
| 2020 Q4 | -31 Million DKK | -55.0% |
| 2019 FY | -50 Million DKK | 70.59% |
| 2019 Q3 | -14 Million DKK | 85.42% |
| 2019 Q4 | -29 Million DKK | -107.14% |
| 2019 Q2 | -96 Million DKK | -207.87% |
| 2019 Q1 | 89 Million DKK | 160.96% |
| 2018 Q1 | 24 Million DKK | 115.09% |
| 2018 FY | -170 Million DKK | -7.59% |
| 2018 Q3 | -31 Million DKK | -82.35% |
| 2018 Q2 | -17 Million DKK | -170.83% |
| 2018 Q4 | -146 Million DKK | -370.97% |
| 2017 FY | -158 Million DKK | -158.52% |
| 2017 Q4 | -159 Million DKK | -412.9% |
| 2017 Q3 | -31 Million DKK | -3000.0% |
| 2017 Q2 | -1 Million DKK | -150.0% |
| 2017 Q1 | 2 Million DKK | -94.44% |
| 2016 Q2 | 72 Million DKK | -41.46% |
| 2016 Q4 | 36 Million DKK | -7.69% |
| 2016 Q3 | 39 Million DKK | -45.83% |
| 2016 FY | 270 Million DKK | -21.51% |
| 2016 Q1 | 123 Million DKK | -11.51% |
| 2015 Q4 | 139 Million DKK | 124.19% |
| 2015 Q1 | 89 Million DKK | 456.25% |
| 2015 Q2 | 54 Million DKK | -39.33% |
| 2015 FY | 344 Million DKK | 90.06% |
| 2015 Q3 | 62 Million DKK | 14.81% |
| 2014 Q4 | 16 Million DKK | -38.46% |
| 2014 FY | 181 Million DKK | 196.72% |
| 2014 Q3 | 26 Million DKK | -16.13% |
| 2014 Q2 | 31 Million DKK | -71.3% |
| 2014 Q1 | 108 Million DKK | 170.0% |
| 2013 Q2 | -30 Million DKK | -171.43% |
| 2013 FY | 61 Million DKK | -70.81% |
| 2013 Q3 | 9 Million DKK | 130.0% |
| 2013 Q1 | 42 Million DKK | 380.0% |
| 2013 Q4 | 40 Million DKK | 344.44% |
| 2012 Q3 | 56 Million DKK | -56.25% |
| 2012 Q2 | 128 Million DKK | 220.0% |
| 2012 Q1 | 40 Million DKK | 110.53% |
| 2012 Q4 | -15 Million DKK | -126.79% |
| 2012 FY | 209 Million DKK | 4.5% |
| 2011 Q4 | 19 Million DKK | 280.0% |
| 2011 Q2 | 8 Million DKK | -93.7% |
| 2011 Q3 | 5 Million DKK | -37.5% |
| 2011 Q1 | 127 Million DKK | 176.09% |
| 2011 FY | 200 Million DKK | 56.25% |
| 2010 FY | 128 Million DKK | 8.47% |
| 2010 Q3 | 5 Million DKK | -37.5% |
| 2010 Q1 | 75 Million DKK | 150.0% |
| 2010 Q4 | 46 Million DKK | 820.0% |
| 2010 Q2 | 8 Million DKK | -89.33% |
| 2009 FY | 118 Million DKK | 24.21% |
| 2009 Q4 | 30 Million DKK | 7.14% |
| 2009 Q3 | 28 Million DKK | 2900.0% |
| 2009 Q2 | -1 Million DKK | -101.82% |
| 2009 Q1 | 55 Million DKK | 0.0% |
| 2008 FY | 95 Million DKK | -46.33% |
| 2007 FY | 177 Million DKK | 637.5% |
| 2006 FY | 24 Million DKK | -99.44% |
| 2005 FY | 4.3 Billion DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 748.32% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 7490.386% |
| SQZ Biotechnologies Company | -79.46 Million USD | 711.598% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -817.345% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -646.166% |
| Mesoblast Limited | -87.95 Million USD | 652.549% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 26795.552% |
| Genus plc | 7.9 Million USD | -6051.899% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 4562.097% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 13198.904% |
| Marizyme, Inc. | -65.34 Million USD | 843.723% |
| ContraFect Corporation | -65.15 Million USD | 845.936% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 5595.251% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 10046.658% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 28233.873% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 16902.69% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 6130.015% |
| MultiCell Technologies, Inc. | -380.07 USD | 127871281.624% |
| Accustem Sciences Inc. | -3.74 Million USD | 13072.388% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 1040.184% |
| EV Biologics, Inc. | -1.26 Million USD | 38454.27% |
| Q BioMed Inc. | -2.05 Million USD | 23783.137% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 13119.02% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 76949.244% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 20512.706% |
| Biomind Labs Inc. | -1.21 Million USD | 40122.432% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 4707.509% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 6249.491% |
| Skye Bioscience, Inc. | -37.64 Million USD | 1391.016% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 22498.233% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 3245292.308% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 7059.923% |
| IMV Inc. | -36.48 Million USD | 1432.029% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 3162.103% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 8454.459% |
| GB Sciences, Inc. | -1.36 Million USD | 35791.284% |
| Alpha Cognition Inc. | -13.77 Million USD | 3628.754% |
| HST Global, Inc. | -146.21 Thousand USD | 332498.605% |
| CSL Limited | 2.64 Billion USD | 81.605% |
| Halberd Corporation | -79.67 Thousand USD | 610070.38% |
| Enzolytics Inc. | -2.17 Million USD | 22426.022% |
| Resverlogix Corp. | -3.61 Million USD | 13562.604% |
| Affymax, Inc. | -14.42 Million USD | 3469.384% |
| SYBLEU INC | -180.3 Thousand USD | 269644.769% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 15424.288% |
| argenx SE | -295.05 Million USD | 264.716% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 876.37% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -495818.367% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 12332.591% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 16160.09% |
| AVAX Technologies, Inc. | -6.41 Million USD | 7677.591% |
| Zenith Capital Corp. | -10.59 Million USD | 4686.636% |
| Genscript Biotech Corporation | -95.47 Million USD | 609.023% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 2091142.079% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 11822.323% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 804195.127% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 913.724% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 15768.483% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | 46120.243% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 25032.679% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 12825.844% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 24338.011% |
| BioStem Technologies, Inc. | -8.48 Million USD | 5829.116% |
| ONE Bio Corp. | 8.67 Million USD | -5501.265% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 110211.947% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 36492.745% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 27795.922% |
| Agentix Corp. | -1.37 Million USD | 35465.748% |
| LadRx Corporation | 400.44 Thousand USD | -121265.588% |
| Cell Source, Inc. | -5.32 Million USD | 9233.258% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 117073.421% |
| Regen BioPharma, Inc. | 1.02 Million USD | -47383.752% |
| Regen BioPharma, Inc. | 1.02 Million USD | -47383.752% |
| NovAccess Global Inc. | -4.76 Million USD | 10290.416% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -6918.462% |
| Itoco Inc. | -1.86 Million USD | 26103.28% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 11039.7% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 29219.233% |
| Kadimastem Ltd | -3.3 Million USD | 14794.331% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 177860.221% |
| CytoDyn Inc. | -49.84 Million USD | 1075.101% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 615033.003% |
| Mobile Lads Corp. | -2.26 Million USD | 21573.146% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 213139.228% |
| Qrons Inc. | -789.34 Thousand USD | 61669.88% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 51718.166% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 23379.407% |
| Rebus Holdings, Inc. | -1.02 Million USD | 47747.059% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 30235.106% |
| International Stem Cell Corporation | -131 Thousand USD | 371092.366% |
| Bioxytran, Inc. | -4.28 Million USD | 11455.135% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 895589.387% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 19307.611% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 1110.984% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 23089.593% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 62336.918% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 15440.909% |
| Neutra Corp. | -233.46 Thousand USD | 208268.248% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 2495.151% |
| PureTech Health plc | -65.69 Million USD | 839.76% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 2385.28% |
| IXICO plc | -1.17 Million USD | 41356.367% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 4995.739% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 950.721% |
| CSL Limited | 2.64 Billion USD | 81.605% |
| Cellectis S.A. | -103.17 Million USD | 571.05% |